Bristol Myers' Psoriasis Med Deucravacitinib Superior To Amgen's Otezla, New Data Shows

Bristol-Myers Squibb Co (NYSE: BMY) has announced new data from its two Phase 3 trials POETYK PSO-1 and POETYK PSO-2 for deucravacitinib, its oral, selective TYK2 inhibitor for moderate to severe plaque psoriasis.
Data were presented at the 2021 American Academy of Dermatology Virtual Meeting Experience.
In both pivotal studies, the psoriasis drug was superior to placebo and Amgen's Otezla, the current oral standard of care, including measures of durability and maintenance of response.
Specifically, deucravacitinib showed superior skin clearance compared with Otezla for key secondary endpoints, including PASI 75 and sPGA 0/1 responses at week 16, with an increased benefit versus Otezla at week 24 and maintained through week 52.
Additionally, deucravacitinib was superior to Otezla across both studies in multiple other secondary endpoints, demonstrating significant and clinically meaningful efficacy improvements in symptom burden and quality of life measures.
Price Action: BMY shares are up 0.06% at $66.35 in market hours on the last check Friday.